Sequential Use of 90Y Microspheres Radioembolization and 177Lu-Dotatate in Pluri-Metastatic Neuroendocrine Tumors: A Case Report

다국어 초록 (Multilingual Abstract)

Abstract 90Y radioembolization and peptide-receptor radionuclidetherapy (PRRT) with177Lu-DOTATATE are both effectivetreatments for patients with inoperable neuroendocrinemetastatic tumors (NET). We report the case of a 72-year-oldman with severe functional syndrome due to a metastaticNET. 68Ga-DOTATOC positron-emission tomography (PET)revealed high somatostatin receptor expression in a gross livermetastasis, in one abdominal lymph node and in severals k e l e t a l l esions. The patient underwent l iverradioembolization with 90Y-resin microspheres followed byfour cycles of PRRT with177Lu-DOTATATE. After 3 months,a complete remission of the functional syndrome was observed.
68Ga-DOTATOC PET demonstrated a complete responsefor skeletal and lymph nodal lesions with a residualbulky mass in the liver. Therefore a further 90Yradioembolization was performed as consolidation treatmentfor the hepatic lesion. Six months after these combined treatments,68Ga-DOTATOC PET demonstrated complete metabolicresponse in liver and stable extrahepatic lesions. Nosignificant long-term adverse reactions were registered. Toour knowledge, the sequential use of 90Y radiembolizationbefore and after PRRT in a liver-dominant advanced NET hasnot been reported in the literature and this case suggests thatthese combined treatments can be safe and effective.

참고문헌 (Reference)

1 Vasamiliette J, "Treatment monitoring with 18 F-FDG PET in metastatic thymoma after 90Y-DOTATOC and selective internal radiation treatment (SIRT)" 12 (12): 271-273, 2009

2 Emami B, "Tolerance of normal tissue to therapeutic irradiation" 21 : 109-122, 1991

3 Rajekar H, "Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment" 2011 : 404916-, 2011

4 Lam MG, "Safety of repeated yttrium-90 radioembolization" 36 : 1320-1328, 2013

5 King J, "Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases" 113 (113): 921-929, 2008

6 Cianni R, "Radioembolisation with (90) Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer" 23 (23): 182-189, 2013

7 Van Essen M, "Peptide-receptor radionuclide therapy for endocrine tumors" 5 (5): 382-393, 2009

8 Delpassand ES, "Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience" 43 : 518-525, 2014

9 McStay MK, "Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy" 237 : 718-726, 2005

10 O’Toole D, "Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours" 19 (19): 585-594, 2005

11 D’Arienzo M, "Absorbed dose to lesion and clinical outcome after liver radioembolization with 90Y microspheres: a case report of PETbased dosimetry" 27 : 676-680, 2013

12 Basuroy R, "A multimodal approach to the management of neuroendocrine tumour liver metastases" 2012

13 Modlin IM, "A 5-decade analysis of 13, 715 carcinoid tumors" 97 (97): 934-959, 2003

14 Ezziddin S, "90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy" 53 : 1663-1669, 2012

15 Paganelli G, "177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study" 2014